Local hemostatic agent
SUBSTANCE: agent further contains aluminium and/or magnesium oxides and satisfies the formula: CaO·(SiO2)m·(M)n·(H2O)k, where M is Al2O3 and/or MgO; m=0.5-3.0; n=0.01-0.05; k=0.2-1.2.
EFFECT: shorter time for onset of hemostasis and low exothermic effect during interaction with blood.
2 tbl, 9 ex
The invention relates to medicine, specifically to the means used to stop the massive bleeding, and can be used as a local hemostatic agents to protect the lives and health of people exposed to extreme factors.
Known drug to stop arterial bleeding from a mixture of fine calcium carbonate, boehmite nanoparticles (metagalaxies aluminum) and polysaccharide (EN 2333002), which does not cause pain and chemical burns of exposed tissues, allowing you to reduce the exothermic effect of hydration and thus the heat transferred to the wound. In addition it does not contain substances which are able to give a solidified mass which causes injury to the edges of wounds. The disadvantage of this drug is its low hemostatic efficacy.
Known composition based on mineral powders, consisting of a mixture of clay materials bentonite, montmorillonite, kaolin, kaolinite, with the specified particle sizes (US 20080319476), providing 100%survival of laboratory animals with arterial bleeding. However, the use of such a composition is not safe due to the potential for embolism vessels by entering into the circulatory system subdesertic particles smatovich clays (Journal of Trauma-Injury Infection and Criticl Care. Kheirabadi BS, MR Scherer, Estep JS, Dubick MA, Holcomb JB. Determination of efficacy of new hemostatic dressings in a model of extremity arterial hemorrhage in swine. 2009; 67(3): 459-459).
It is also known local hemostatic agent to stop intensive arterio-venous bleeding (EN 2414225), including a mix of synthetic zeolites
type CAA formula mCaO·nNa2O·2SiO2·Al2O3·0,5H2O and
type Sakh formula mCaO·nNa2O·2.5SiO2·Al2O3·0,5H2O,
the crystal lattice which contain cations of calcium in the amount of 8÷10 wt.% when the ratio of these components, wt.%:
|synthetic zeolite mCaO·nNa2O·2SiO2·Al2O3·0,5H2O||- 70÷80,|
|synthetic zeolite mCaO·nNa2O·2.5SiO2·Al2O3·0,5H2O||- 30÷20,|
and when the ratio n:m, equal 0,13÷0,22.
The solution that is closest to the claimed invention taken as a prototype.
The disadvantage of the invention of the prototype is high, up to 85°C, the temperature during contact of the zeolite material with blood, resulting in thermal burn tissues caused by heat generation at the contact of the zeolite with the aqueous environment of the blood plasma due to the high value of the heat of hydration. Another disadvantage of the invention is a high-cost multi-stage method for the synthesis of the target product.
The technical task of the invention is to develop an effective hemostatic local actions, not giving a high exothermic effect when interacting with the blood produced from inexpensive commercially available raw material, which is important in organizing and providing first and primary health care to stop parenchymal venous and arterial bleeding.
The invention is aimed at finding local hemostatic agents in a series of inorganic sorbents with high absorbent capacity of the blood, characterized by a short time of the onset of hemostasis, not giving a high exothermic effect when interacting with the blood produced from inexpensive commercially available raw materials.
The technical result of the claimed invention is achieved by the fact that the proposed local hemostatic agent based on synthetic calcium hydrosilicate, characterized by short time of the onset of hemostasis and low exothermic effect in the interaction with blood which further comprises oxides of aluminum and/or magnesium and is responsible formula unit:
m=0,5÷3,0; n=0,01÷0,05; k=0,2÷1,2.
The stated number of moles of silicon oxide (m) is determined by the conditions of synthesis of calcium hydrosilicate with the formation of macropores.
The number of moles of aluminum oxide and/or magnesium oxide is selected to ensure optimal micro porosity of the final product, which occurs in the process of its synthesis at the expense of hydrogen by the reaction of the powders of aluminum and/or magnesium introduced into the reaction mixture with water with the formation of oxides of aluminum and/or magnesium. When the value of n is less than 0.01 the obtained calcium hydrosilicate loses the ability to hemostasis due to the low micro porosity and, as a consequence, the decrease in the sorption capacity of the product in the blood. When the n value is more than 0.05 obtained calcium hydrosilicate loses mechanical strength due to the high porosity, which leads to its destruction by contact with blood.
The number of moles of water is determined on the basis of laboratory test results, according to which when the value of k is less than 0.2 mol of the obtained calcium hydrosilicate loses the ability to hemostasis, as destroyed the porous structure of the product, which is more than 80% is converted to inert with respect to blood calcium salt of metasilicic acid CaSiO3and when the value of k b is more 1,2 there is a significant reduction of hemostasis due to the decrease in the sorption capacity of the product in the blood.
The invention consists in that the refined composition of the synthetic calcium hydrosilicate with the inclusion of oxides of aluminum and/or magnesium that have the property to stop the massive bleeding, not giving a high exothermic effect in the interaction with blood and made from inexpensive commercially available raw materials.
Below are the best examples of embodiments of the invention from the point of view of the sorption ability of the proposed drug. The invention is implemented as follows.
The mixture of powders 56 kg of calcium hydroxide mark "h" according to GOST 9262-77, 72 kg of Aerosil (colloidal silicon dioxide (SiO2)) brand ASKO-175 according to TU U 2101-31695418-002-2003 and 1 kg of a powdered aluminum grade PAP-1 or 0.5 kg of magnesium powder brand MPF-4 according to GOST 6001-73 shut in 100 l of water. The resulting dough is loaded into the form of stainless steel that are placed on the shelves of the autoclave type 2 H. Zatvorenog the mixture is treated with saturated steam with temperature (175÷200°C under pressure (0,9÷1,6) MPa for 6 hours. At the end of the process of steaming produce steam release into the atmosphere, cooling the autoclave and unloading forms. The result is calcium hydrosilicate, saturated with macropores formed during crystallization and evaporation of water, and the micropores formed stand out bodoro the om by the reaction of the powders of aluminum or magnesium with water, accompanied by the formation of oxides of aluminum and/or magnesium.
The briquettes obtained porous synthetic calcium hydrosilicate are extracted from the molds and passed through a jaw crusher. The resulting powder was classified into fractions of 0.1÷0.3 mm, 0,25÷1.25 mm 0,3÷5,0 mm 5,0÷10,0 mm
To increase the absorbent capacity of the obtained synthetic calcium hydrosilicate blood spend his subsequent annealing at 200°C for 1 hour or contactless heating in the electromagnetic field of the microwave radiation at power microwave 1000 W at a frequency of 2450 MHz radiation for 30 minutes under the conditions of this treatment, the evaporation of molecular water and removing a portion of the absorbed water from the micropores of the product. Get either Cao·1,2SiO2·0,025Al2O3·0,7H2O or Cao·1,2SiO2·0,04MgO·0,2H2O, are shown in Table 2, examples 5 and 6.
The finished product is heated to a temperature of 80÷90°C, Packed in sealed packs of combined packaging material type Teratol and subjected to radiation sterilization.
General physic-chemical properties of the drug are presented in Table 1.
|1||Fractional composition: wt.%,|
|the number of grains less than 0.3 mm and not more than||3|
|the number of grains more than 5.0 mm, max||3|
|2||Specific surface area by BET, m2/g, not less than||40|
|3||The total porosity, ml/g, not less than||4·10-2|
|4||Sorption capacity, g/g|
|- water fluid., not less than,||1,0|
|by blood, not less,||1,2|
|5||the pH of aqueous extract||7,0-9,5|
|6||The temperature increase in the interaction with blood, hail. With, not above||45|
The values of porosity and sorption ability of calcium hydrosilicate, optionally containing oxides of aluminum and/or magnesium, if p is the applicatio provide a stop massive bleeding due to the implementation of hygroscopic mechanism of hemostasis, leading to the binding of water and solutes in the area of defect vessels and the local concentration of cellular and major protein components of the blood (including clotting factors). This, in turn, induces the formation of a blood convolution. The effect of stopping the bleeding increases due to the high calcium content in the product, which is a cofactor in many parts of the coagulation cascade, but also due to the surface potential of crystals of calcium hydrosilicate, contributing to the activation of factor XII clotting and platelets.
Below are examples of the results of laboratory tests of funds committed by known methods (patent RU 2127428, THE 9393-001-18152288-2009), are summarized in Table 2: "the timing of hemostasis and the sorption capacity of the blood of the inventive hemostatic agents".
|# example||The hemostatic composition||The timing of hemostasis, s||The sorption capacity of the blood, g/g||Temperature interaction hemostatic blood, °C|
|7||CaO·2,9SiO2·0,01 Al2O3·1 2N2About||8||1,5||44|
|75% of CaO·0,1Na2O·2SiO2·Al2O3·0.5H2O||10||0,5||85|
To assess the effectiveness of funds conditional name "GameStop-M) experimental studies on the mini-pigs Svetlogorsk breed. The study selected 27 animals, formed into 3 groups: two experimental and one control, 9 animals in each. The objective of the experiment was to study the effectiveness of the drug on the model seriously injured groin damage femoral vascular bundle. In another group of animals was used by local hemostatic tool prototype (code name "GameStop is), which compared the data obtained. In the control group applied a pressure bandage to the wound using a personnel dressing tool PPI-AV. After drawing the wounded and the short period of uncontrolled hemorrhage, the preparation was filled into the wound, then was carried out by manual compression for 7 min, after which assessed the adequacy of hemostasis by the number of recurrent bleeding, survival time and volume of blood loss. The duration of the acute experiment was 180 minutes
"GameStop-M showed significantly high survival rates of 100%, comparable with the local hemostatics "GameStop", whereas in the control group survived only 13% of the animals. The use of local hemostatic agents contributed to the decrease in the volume of blood loss. After treatment in groups where used "GameStop-M" and "GameStop, volume of blood loss averaged 350,62 and 423,12 ml, respectively, compared to control, where animals lost an average of 1522,29 ml in experimental groups was significantly higher than the survival time. In the control group, the average did not exceed of 37.8 minutes parameters are consistent with the rate of recurrent bleeding, which in animals in the experimental groups was significantly less (22,2% 33,3% compared to 71.2 percent control).
Also performed preclinical studies is and the Romanov sheep breed. The similarity of their anatomical and physiological parameters of the cardiovascular system (the caliber of blood vessels, blood pressure, response to stress factors) increased the validity of the experiment, which was attended by 12 animals. Animals were randomized into 3 groups of 4 animals each. As in the previous study assessed the effectiveness of the "GameStop-M" on the model of injured groin. The design of the experiment is similar to the above.
In the group where used "GameStop-M"sustainable primary hemostasis was achieved in 3 cases out of 4 (75.0 per cent). 1 animal after the resumption of bleeding "Gesatop-M was applied again with a positive effect. In the end, all the animals in the 1st experimental group survived to the end of the experiment. Recurrence of bleeding was observed in 1 case after raising systemic blood pressure in response to intravenous infusion. In 1-St and 2-nd experimental groups data on the number of surviving animals and the frequency of recurrence of bleeding reliable and comparable.
In the control group, all animals died prematurely. The frequency of recurrence of bleeding was 100%. When comparing data obtained in both experimental groups, which was used hemostatic agents, differences in the volume of blood loss was not (Mann-Whitney test, p≤0,001), whereas in the experimental group animals were lost on average 1430,12 ml more blood C the experiment.
Mini-pigs Svetlogorsk breed evaluated the effectiveness of the "GameStop-M" on the model of parenchymal bleeding in the injured liver. When comparing two local hemostatics "GameStop-M" and "GameStop" with the control group, in which the bleeding was stopped only by tamponade, it was shown a significant difference in survival rates in experimental animals. In the control group sustained hemostasis was not achieved, all the animals died during the experiment from irreversible blood loss. Whereas in the 1-St and 2-nd experimental groups, the level of survival was equal 88,9 and 78.8%, respectively. When comparing experimental groups with each other, significant differences were not found. Another important characteristic influencing mortality is estimated blood loss. In the performed study defined amount of blood loss before treatment, which in all groups was comparable, as well as blood loss after application of hemostatic and total volume. The average figures indicate significantly higher blood loss in the control animals. It is determined that the effectiveness of the "GameStop-M" and "GameStop" when you stop parenchymal bleeding comparable.
On models injured groin investigated the security of GameStop-M within the study of thermal effects on tissues. When temperature measurement has been shown that the maximum p is the same rise in the wound does not exceed 45°C, compared with Hemotoma" where the temperature in the wound was 85°C. When using "GameStop-M researchers subjectively did not report excessive heating of the drug in the wound. At the end of the experiment, after removal of hemostatic from the wound, visual inspection revealed no signs of coagulation necrosis of soft tissues. The edges of the skin wound remained intact. Histological examination revealed no signs of necrosis. Post-traumatic changes in an intim vessels, soft tissues were not significantly different from control biopsies.
Thus, the invention opens the possibility to provide first and primary health care to stop parenchymal venous and arterial bleeding effective hemostatic agent local action, not giving a high exothermic effect when interacting with the blood produced from inexpensive commercially available raw materials.
Local hemostatic agent based on synthetic calcium hydrosilicate, characterized by short time of the onset of hemostasis and low exothermic effect in the interaction with blood which further comprises oxides of aluminum and/or magnesium and meets formula one:
m=0,5÷3,0; n=0,01÷0,05; k=0,2÷1,2.
SUBSTANCE: invention refers to medicine, namely to hematology and oncology, and concerns correction of amegakaryocytic thrombocytopenia. That is ensured by introducing a platelet concentrate and performing autologous peripheral haemopoietic stem cell transplantation with performing a single subcutaneous injection of romiplostim 200-300 mcg on the day of the transplantation.
EFFECT: method provides reducing a risk of the haemorrhagic complications following the high-dose chemotherapy, ensured by the fast and effective platelet growth.
2 ex, 1 tbl
SUBSTANCE: agent contains chitosan salt 75-95 wt % of polydisperse powders of chitosan hydrochloride, hydrobromide, formate, acetate, succinate, citrate, glycolate or lactate and polyhexamethylene guanidine hydrochloride 4-20 wt %. The chitosan salt and polyhexamethylene guanidine hydrochloride are covalently cross-linked by a polyfunctional compound 1-5 wt % of glycidyl ethers. The chitosan salt is specified with an average particle size of 0.2÷2.0 mm, degree of chitosan deacetylation 0.75÷0.95, and molecular weight 10÷500 kDa. The above polyfunctional compound of glycidyl ethers is presented by a diglycidyl ether of butandiol, di- or triethylene glycol or propylene glycol, oligoethylene oxide, as well as triglycidyl ethers of glycerol or trimethylol propane.
EFFECT: method possesses high blood sorption capacity, rapid hemostasis time and high antimicrobial activity.
3 cl, 2 tbl, 12 ex
SUBSTANCE: invention represents a hemostatic preparation containing a complex of aminocaproic acid and ferric iron stabilised with sodium chloride in the isotonic concentration. The invention aims at wound healing, small hemostasis at administering the first medical aid at the pre-hospital emergency evacuation.
EFFECT: what is provided is preparing the preparation very soluble in water and possessing high hemostatic activity, low costs and extended storage period.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to an antiseptic drug with haemostatic action for wound cleaning. The drug contains ingredients in the following ratio, wt %: an antimicrobial substance - 0.01-3, an active complex - 1-25, glycerol - 2-35 and water - up to 100. The antimicrobial substance is specified in a group consisting of cetyl pyridinium or cetyl methyl ammonium halogenide, chlorhexidine, miramistin and other quaternary bases applicable in medical practice to treat burns and to clean open wounds, and the active complex is presented by a haemostatic preparation in the form of a mixed-ligand chelated complex of zinc, ethylene diamine tetraacetic acid and ε - aminocapronic acid. The invention also refers to a method for preparing the antiseptic drug with haemostatic action. The method consists in the fact the active complex is prepared in a water-glycerol mixture while stirring by dissolving ε - aminocapronic acid, then zinc oxide, adding powdered ethylene diamine tetraacetic acid and after dissolved completely, adding a liquid solution of the antimicrobial substance in the water-glycerol mixture.
EFFECT: preparing the antiseptic drug with haemostatic action for wound cleaning.
2 cl, 9 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics. There are developed agent for forming a biogel, biogels for hemostasis, wound closure, tissue engineering and targeted drug delivery. The agent contains a soluble carrier whereon a number of fibrinogen-binding groups is immobilised. The biogel that contains fibrinogen molecules and a number of soluble carriers applicable for intravenous and/or local administration; each carrier comprises a number of fibrinogen-binding groups immobilised on the carrier, and each fibrinogen molecule is bound to at least two fibrinogen-binding groups so that the fibrinogen molecules occurs to be bound to each other through the carriers by non-covalent bonds between the fibrinogen-binding groups and the fibrinogen molecules. The biogel containing fibrin monomers and a number of soluble carriers applicable for intravenous and/or local administration, wherein each carrier comprises a number of fibrinogen-binding groups immobilised on the carrier, while the fibrin monomers are bound to each other through the carriers by non-covalent bonds between the fibrinogen-binding groups and the fibrinogen monomers. The biogel containing fibrin and a number of soluble carriers applicable for intravenous and/or local administration, wherein each carrier comprises a number of fibrinogen-binding groups immobilised on the carrier with the fibrin monomers in fibrin are covalently bound to each other by peptide bonds, and the fibrin monomers in fibrin are bound to each other through the carriers by non-covalent bonds between the fibrinogen-binding groups and the fibrinogen monomers. A method for forming the biogel involving a contact of the fibrinogen molecules with a number of soluble carriers. A method for hemostasis by topical administration of the biogel at a haemorrhage or a wound. Using a number of soluble carriers applicable for intravenous and/or local administration. A pharmaceutical formulation for topical administration containing the biogel, agent or a number of soluble carriers.
EFFECT: using the declared invention enables preparing the agents requiring no toxic reagents to be used, have a minimal risk of allergic reactions, and are easy to prepare and use.
2 tbl, 4 dwg, 5 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry, and represents a haemostatic agent used in small cuts, characterized by the fact that it is represented in the form of a match with its head having the following formulation, wt %: sodium chloride - 0.58 - 0.71; ε-aminocaproic acid - 2.14 - 3.25; purified water - 60.93 - 73.98; aluminium potassium sulphate - 19.65 - 32.84; lanolin - 1.77 - 2.92.
EFFECT: invention provides creating the agent which has the non-burning haemostatic agent when applied on the small cuts.
SUBSTANCE: group of inventions refers to medicine and aims at conducting the endoscopic hemostasis in gastric-duodenal hemorrhages. For the purpose of conducting the hemostasis, the capillary hemostasis liquid "Hemostab" is used and accompanied by the injection compression infiltration of paravasal and periulcerous regions. "Hemostab" is introduced within a hemorrhage point that is followed by the argon-plasma coagulation.
EFFECT: using the declared group of inventions is effective for the hemostasis in gastric-duodenal hemorrhages; it has the positive local effect on the clinical course of the pathological process, reduces the length of recovery of the defects caused the hemorrhage with no toxicity of the above preparation and no allergies.
1 ex, 3 dwg, 6 cl
SUBSTANCE: group of inventions refers to medicine, particularly to treating hemophilia. The factor IX conjugates are modified to include a biocompatible polymer fragment. The factor IX conjugates are substantially free from the factor IXa contaminations. The factor IX conjugates have the improved pharmacokinetic properties such as an extended half-life.
EFFECT: group of inventions enabling reducing the dosage and rate of administration, and also reduces the risk of hemarthrosis, hemorrhage, gastrointestinal bleeding, and menorrhagia in mammals suffering hemophilia B.
30 cl, 4 dwg, 9 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to preparing a drug possessing antiulcerogenic, antistress and hemostatic activities. The declared method involves mixing the dry extracts of great nettle leaves, knotgrass herb and nosebleed herbs with fine powders of ginger rhizomes and cinnamon bark in ratio, weight fraction 35: 30 : 10 : 20 : 5. The above dry extracts prepared by multiple extraction of the herbal raw materials in ethanol and water, filtration of the prepared extracts, evaporation thereof, concentration and drying in a vacuum oven, wherein the first and second extractions of the herbal material is carried out in 80% ethanol, the third and fourth extractions - in 40% ethanol, and the fifth and sixth extractions - in boiled water.
EFFECT: invention provides preparing the effective and safe drug for preventing the digestive diseases.
7 tbl, 1 ex
SUBSTANCE: invention relates to field of medicine and is intended for treatment of hyperfibrinolytic hemorrhages in cardio surgery. Method includes irrigation of pericardium cavity and/or pleural cavity with solution of antifibrinolytic. Solution is introduced during hemorrhage against the background of hyperfibrinolysis after suturing postoperative wound.
EFFECT: method application makes it possible to reduce postoperative hemorrhage, need of transfusion of blood components and necessity of additional surgical hemostasis, ensures maximal concentration of active substance in area of maximal activity of fibrinolysis and in immediate proximity from source of hemorrhage, excluding risk of thrombosis.
SUBSTANCE: invention relates to a concentrated acid component for bicarbonate hemodialysis. The acid component includes sodium (Na+) in an amount of 2450.0-4550.0 mEq/l, chlorine (Cl-) in an amount of 2453.5-4553.5 mEq/l, hydrogen H+ (hydrochloric acid), succinate and citrate, each in an amount of 3.5-98.0 mEq/l. The invention also relates to a diluted acid component for bicarbonate hemodialysis, which includes sodium chloride 70.0-130.0 mEq/l, hydrochloric acid 0.1-2.8 mEq/l, succinic acid 0.1-2.8 mEq/l, and citric acid 0.1-2.8 mEq/l. The invention also relates to a concentrate for preparation of the acid component, which contains hydrochloric acid in a liquid form, and all other components in a dry form, as well as to a method of obtaining the acid component, which includes dissolution of dry chemical reagents from the said concentrate in water and addition of liquid reagents.
EFFECT: invention ensures obtaining a solution for dialysis, applied in case of acute and chronic renal failure.
14 cl, 1 tbl, 3 ex
SUBSTANCE: invention refers to medical and veterinary traumatology, surgery and concerns treating various bone injuries, particularly fractures and fissured fractures. That is ensured by fixing injured bone fragments with a plaster splint or a polymer bandage. An aqueous solution containing 1-hydroxyethylene diphosphonic aicd in an amount of 1.80-2.06 g/l, anhydrous calcium chloride in an amount of 1.44-2.22 g/l, gadolinium (III) nitrate hexahydrate in an amount of 0.30-0.40 g/l, dysprosium (III) chloride hexahydrate in an amount of 0.038-0.076 g/l is introduced into the fracture; pH of the solution is 7.3-7.8. Before administering into the fracture, the above agent is heated up to 30-100°C, kept at this temperature for 1-48 hours, and cooled to room temperature.
EFFECT: method provides reducing the osteoanagenesis time within the injury, including by providing the optimal thermodynamic crystalline maturing with low toxicity of the solution and its storage stability.
3 tbl, 35 ex
SUBSTANCE: invention relates to medicine, namely to a method of preventing complications of rhinitis or an influenza-like syndrome. The method of preventing complications of rhinitis or the influenza-like syndrome consists in the following: an isoosmotic ionic sea water-based solution with osmolarity, equal to 250-350 mOsm/kg, is introduced daily into each nostril of patients suffering from rhinitis or the influenza-like syndrome, and at the remission stage in the certain regimens.
EFFECT: increased method efficiency.
9 cl, 13 dwg, 13 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, particularly to a pharmaceutical composition for treating bronchitis. The pharmaceutical composition for treating bronchitis contains a powder of FRITILLARIAE THUNBERGII BULBUS; a concentrated ethanol extract of EPHEDRAE HERBA, FORSYTHIAE FRUCTUS, SCUTELLARIAE RADIX, ARMENIACAE SEMEN AMARUM, PINELLIAE RHIZOMA, ARCTII FRUCTUS and RHEI RADIX ET RHIZOMA; a concentrated aqueous extract of GYPSUM FIBROSUM, MORI CORTEX, PEUCEDANI RADIX, CITRI RETICULATAE PERICARPIUM, LONICERAE FLOS, PLATYCODONIS RADIX and GLYCYRRHIZAE RADIX ET RHIZOMA.
EFFECT: declared pharmaceutical composition is effective for eliminating cough, dissolving phlegm, relieving asthma and inflammation; it provides the positive therapeutic effect in treating bronchitis.
11 cl, 10 tbl, 12 ex
SUBSTANCE: method of treating periodontitis provides professional hygienic oral cleansing, antiseptic therapy, local drug-induced therapy. The local drug-induced therapy is two-staged with the use of zeolite-containing fossil flour with particle size of 0.3-0.4 mm. The first stage involves gingival infriction of a mixture consisting of zeolite-containing fossil flour and distilled water taken in equal weight parts for 10-15 min; the second stage includes applications of tampons impregnated with a mixture containing 2.5-3 weight parts of fossil flour and 1-1.5 weight parts of distilled water on the affected gingiva; the length of the local drug-induced therapy is 12-14 days.
EFFECT: effective treatment of periodontitis enables stable reduction of periodontal inflammation, fastening the remission time and reducing the number of aggravations.
2 tbl, 4 ex
SUBSTANCE: human recombinant interferon alpha-2b is orally administered into a patient's body as an ingredient of an anti-acid protective medium in a dose of 500 thousand IU twice a day for at least 7 days. The length of the therapeutic course is no more than 14 days. As human recombinant interferon alpha-2b, the preparation contains Reaferon-EC or Reaferon-EC-Lipint; as the anti-acid protective medium, the preparation contains aluminium hydroxide and magnesium hydroxide in the following quantitative ratio: aluminium hydroxide - 25-35 mg/ml; magnesium hydroxide - 15-30 mg/ml; human recombinant interferon alpha-2b - 0.35·105-5·105 IU/ml.
EFFECT: using the given method enables providing higher clinical effectiveness in gastric or duodenal ulcer in a combination with reducing the content of human recombinant interferon alpha-2b in 4 times in a single dose, and in 2 times in a daily dose that is ensured by the preparation delivery directly into the ulcer.
3 cl, 1 tbl, 2 ex
SUBSTANCE: invention relates to medicine and specifically to trauma surgery and orthopaedics, and can be sued for surgical treatment of ununited fractures and false joints of cylindrical bones when there is a shortage of soft tissue. The method involves, 5-6 days before an operation, performing needle biopsy of bone and soft tissue fragments from the damage centre of the cylindrical bone and determining presence and nature of obligate intracellular viral infection (OIVI). Super-selective angiographic analysis of the microvascular channel to the capillary link is also performed. Valtrex is administered to the patient 2-4 days before the operation in a dose of 500 mg twice a day. Further, the method involves performing osteosynthesis or re-osteosynthesis with resection of the ends of bone fragments, opening marrowy canals, bone stimulation and batting the space of the bone defect with a gel-like nanostructured composite implant. In the presence of OIVI, resection of bone fragments is carried out in a larger volume until the onset of "pinpoint bleeding", i.e. to areas with satisfactory intrabone blood supply. The composite implant contains thrombocyte-rich autoplasma, mixed in ratio of 1:(1-2) with granules of a complex alloplastic preparation (CAP) based on hydroxyapatite which contains 50-60 wt % collagen. The composite implant also contains either 0.08-2.8 wt % colloidal solution of nanoparticles of zero-valent silver metal Ag0, or gold Au0, or copper Cu0, or palladium Pd0, or platinum Pt0, or 5-12 wt % nanoparticles of said metals in dry form. The nanoparticles have size of 2-40 nm. A colloidal solution of said nanoparticles or colloidal nanoparticles of said metals in dry form is added to the CAP granules. Further, the prepared granules of the gel-like complex alloplastic preparation are laid in a selected ratio on the layer of thrombocyte-rich autoplasma, without mixing, for subsequent transfer into the bone defect space. In case of performing resection of bone fragments in a larger volume until the onset of "pinpoint bleeding", corticotomy is further performed on the cylindrical bone being operated on, with subsequent distraction of the bone regenerate using any existing method. Further, the bone fragments are repositioned, followed by metallo-osteosynthesis. Before wound suturing, the surface of the area with shortage of soft tissue in the projection of the ununited fracture and false joints is covered by a semi-permeable flexible plate made of the complex alloplastic preparation based on hydroxyapatite, which contains 50-60 wt % collagen. The plate has thickness of 0.25-1.2 mm. The surface area of the plate is 10-20% greater than the area with shortage of soft tissue in the corresponding projection. The part of the erythrocyte mass remaining from preparing the thrombocyte-rich autoplasma and the plasma are returned into the bloodstream of the patient by intravenously using a drip during the surgical procedure or in the early post-operation period. After the operation, valtrex is administered to the patient in a dose of 500 gm once a day for two weeks and then in a dose of 500 mg every other day for two weeks.
EFFECT: method provides reliable prevention of OIVI at a damage centre, normalisation of local microcirculation of blood, avoiding ischemic processes, and compensation for the shortening of the length of the limb of the patient being operated on while preventing weakening of the process of reparative osteogenesis and allergic reactions of the body.
6 cl, 4 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely to clinical allergology, and may be used for extracorporeal allergen denaturation. That is ensured by treating a surface of objects with an allergen-denaturing composition. The composition contains calcium chloride or calcium acetate and lanthanum chloride or lanthanum nitrate in certain proportions.
EFFECT: combinations of the above metal salts selected in certain proportions provide the effective allergen denaturation ex vivo by a synergistic denaturation action of the given ingredients.
9 cl, 4 tbl
SUBSTANCE: declared products are presented in the form of suppositories and contain a mechanically active amorphous or amorphocrystalline calcium gluconate as an active substance and additives as a base. One of the declared agents contains hard fat, paraffin, cacao butter and Lutrol F68 as a base in specific proportions. The other agent contains Witepsol W35, Witepsol H15, kollidon CL and Cremophore RH-40 as a base in specific proportions.
EFFECT: invention provides the agents with uniformly released active substances, prolonged action and applicability for unassisted use by the patients; the declared agents provide a wide spectrum of therapeutic activity, particularly the regulation of Ca2+ and phosphate exchange, reduced resorption and higher bone tissue density, Ca2+ replacement, improved Ca2+ intestinal absorption, phosphate renal re-absorption, bone mineralisation, improved blood coagulation, maintained stable cardiac function, and enabled neurotransmission.
2 cl, 5 ex
SUBSTANCE: invention refers to medicine, particularly to paediatrics, namely to otorhinolaryngology, and may be used in treating chronic tonsillitis in children's health centres, in-patient hospitals, polyclinics. The low-power laser light covers projections of palantine tonsils, namely an anterior lateral neck surface below a mandibular angle to the right and to the left. The laser light is generated at wavelength 0.89 mcm, constantly variable frequency 10 to 1,500 Hz by AZOR 2K-02 apparatus in the contact, stable mode. The exposure length is 1 minute per a field at pulse power 2-3 Wt/pulse daily; the therapeutic course is 7-8 procedures in 5-10-year-old children. The exposure takes 2 minutes per a field at pulse power 4-5 Wt/pulse daily within the therapeutic course making 9-10 procedures. Each physiotherapeutic procedure is preceded by tonsillar lacunae irrigation with sterile 0.9% normal saline using a Hartmann cannula. The method is safe by selecting laser light conditions in the children of various age groups.
EFFECT: method enables higher clinical effectiveness in chronic tonsillitis, prolonging remission, reducing a recurrence and complication rate, lowering the need for medical treatment, improving the quality of life in children and adolescents.
SUBSTANCE: material comprises synthesized material having hydroxyapatite structure and additional ytterbium and erbium ions or ytterbium and thulium ions according to known formula. The material is compositionally equivalent to human skeletal bone tissue and biocompatible with it.
EFFECT: wide range of use in investigating tissue behavior in different fields of surgery and traumatic surgery.